90 results about "Topical uses" patented technology

The invention relates to a product for topical use in the treatment of skin affected by dysbiosis. The product has a pH ranging from 5.5 to 6.5 and essentially comprises water, glycerin and at least one crosslinked polyacrylate. This product can be used as a prerequisite for the transplantation of biological material favorable to the development of a healthy cutaneous bacterial flora.

The present invention relates to a pharmaceutical composition for topical use comprising a corticosteroid and an insecticide selected from pyrethrins or synthetic pyrethroid-based insecticides. Also described are methods of using the compositions of the invention for the treatment of allergic dermatitis, in particular insect bite hypersensitivity, in an animal.

The present invention relates to an oil-in-water emulsion gel comprising tiotropium bromide for topical use. It can be used in cosmetics, as an antiperspirant or in the prevention and / or treatment of hyperhidrosis. After application to the skin nanoparticles are formed and the drug substance penetrates the skin where it exerts its effect. The oil-in-water emulsion gel is composed in such a manner that the drug substance permeates the epidermis and enters into the dermis, but only to a minor extent permeating through the dermis and into the systemic circulation.

The present invention relates to a hyaluronate nanofabric sheet and a manufacturing method therefor and, more particularly, to a hyaluronate nanofabric sheet having excellent percutaneous absorption and physical properties and a manufacturing method therefor. A method for manufacturing a hyaluronate nanofabric sheet according to the present invention comprises the steps of: (a) mixing a hyaluronate having a weight average molecular weight of 5×103 - 5×104 Da and a hyaluronate having a weight average molecular weight of 1×105 - 1×106Da and dissolving same in water to prepare an aqueous hyaluronate solution; and (b) electrospinning the aqueous hyaluronate solution. The hyaluronate nanofabric sheet of the present invention has an excellent transdermal absorption rate due to the ultra-low molecular weight hyaluronic acid as a main component thereof and exhibits excellent physical properties due to a certain amount of medium-molecular weight hyaluronic acid mixed therewith, and as such, can be applied for various purposes, such as mask patches for topical uses, ophthalmic or mucosal drug delivery systems, etc.

Provided herein are compositions for topical use comprising an imidazole or a salt thereof, and domiphen bromide as active ingredients for use in treating or preventing a fungal infection, wherein said imidazole is chosen from ketoconazole and clotrimazole as active ingredients for use in treating or preventing a fungal infection.

A biocompatible adhesive suitable for both internal and topical use. The adhesive is a tissue-adhesive hydrogel formed from an oxidized carboxymethylcellulose (oCMC) with aldehyde functional groups and a methacrylated methylcellulose (mMC).

1. The name of the product of this design: handle of a frying pan. 2. Purpose of the product of this design: Overall purpose of the product: used for cooking food. Local Use of the Product: Used as a handle for a frying pan. 3. The key design point of this design product lies in the shape of the part for which protection is sought. 4. The picture or photo that best illustrates the design points: Stereoscopic diagram 1. 5. The design features of the rear view have been clearly shown in other views, so the rear view is omitted; the bottom surface of the product of this design is a part that is not easy to see or cannot be seen when in use, so the top view is omitted.

The present invention provides a new silicone gel composition suitable for preparing an anti-herpes viruses product of natural origin. The new composition is capable of permeating at the target epidermis side of the skin. The new composition is capable of retaining in the target epidermis side of the skin for a certain period. The present invention also relates to the topical use of the silicone gel composition for the treatment of viruses of the herpes family at a posology regime.

To search for a new active ingredient that is effective in improvement, treatment, and prevention of periodontal disease, and to provide a periodontal disease preventive or therapeutic agent including the new active ingredient.SOLUTION: A periodontal disease preventive or therapeutic agent containing dextromethorphan and / or a salt thereof, an internal or external periodontal disease preventive or therapeutic medicine, and an oral composition for preventing or treating periodontal disease such as a patch, a liniment, a film, a dentifrice, a mouthwash, or a spray, are provided. As the salt of dextromethorphan, dextromethorphan hydrobromide is preferred.SELECTED DRAWING: Figure 2

The present disclosure belongs to the field of pharmaceutical formulations and particularly relates to a composition with a synergistic therapeutic effect on acne lesions and a preparation method therefor and use thereof. The composition provided by the present disclosure comprises active ingredients adapalene and dapsone, which exhibit a synergistic therapeutic effect on inflammatory acne lesions when used in combination. Compared with corresponding single drugs, the composition can significantly reduce the number of inflammatory lesions; meanwhile, relative to the topical use of adapalene alone, the composition of the present disclosure can mitigate skin irritation reactions caused by adapalene and exhibits good safety.

The object of the present invention is Udonitrectag (or Negermin or MTS. IUPAC name (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabicyclo[3.2.1]octane-7-carboxylic acid lysine salt) and pharmaceutical formulation thereof for topical use for use in the treatment of dermatological diseases. i.e. of the skin and mucous membranes.

The present invention provides a new silicone gel composition suitable for preparing anti-herpes virus preparations of natural origin.The new composition has the ability to penetrate into the target epidermal side of the skin.The new composition has the ability to be retained on the target epidermal side of the skin for a certain period of time.The present invention also relates to the external use of the silicone gel composition for the treatment of herpes virus in a posology regime.

1. Name of the product of this design: mouth of a cosmetic bottle. 2. Purpose of the product of this design: The overall purpose is for use as a nail polish bottle or nail polish glue bottle. Topical use is for the mouth of a nail polish bottle or the mouth of a nail polish bottle. 3. The key design point of this design product lies in the shape of the part for which protection is sought. 4. The picture or photo that best illustrates the design points: three-dimensional picture. 5. Other situations that need explanation Other explanations: Partial enlarged figure 1 is an enlarged view of area A in the main view, and partial enlarged figure 2 is an enlarged view of area B in the stereoscopic view; this design requests partial design protection, the part represented by the solid line is the part requested for protection, the part represented by the dotted line is the part not requested for protection, and the dot-dash line is the boundary between the protected part and the unprotected part.

The present invention relates to a composition and method for solubilizing eggshell membrane at convenient rates. The present invention also relates to organoleptically acceptable products obtained therein, and to their oral or topical application to improve a disease or condition in a subject.

1. The name of the product of this design: the main body of a disposable atomizer. 2. Purpose of this design product: Overall purpose: used as an accessory for electronic cigarettes. Topical Use: For use as the body of a disposable nebulizer. 3. The key design point of this design product lies in the shape of the part for which protection is sought. 4. The picture or photo that best illustrates the key points of the design: Design 1 Stereoscopic drawing 1. 5. Designate Design 1 as the base design.

A method for reducing the amount of sebum produced by human skin and / or by the scalp, for preventing, reducing, slowing down, stopping, and / or attenuating the appearance of unsightly, uncomfortable, and / or unpleasant manifestations of the skin and / or scalp in humans due to the secretion of sebum includes topically applying an extract of the alga Halopteris scoparia. Cosmetic or pharmaceutical compositions, in particular dermatological compositions, for topical use, containing an extract of the alga Halopteris scoparia, are also described.

Pharmaceutical compositions for topical use containing diclofenac in the form of salt with epolamine, present at concentrations higher than 2.0% by weight are described. Such compositions provide, with respect to those currently available, a more complete absorption of the administered dose, reducing the dispersion of active ingredient and allowing treatments requiring the administration of high and accurate dosages to be carried out.

Self-emulsifying formulation for topical, and typically skin use, comprising at least one highly lipophilic active component, a lipophilic portion, an amphiphilic portion, and a skin penetration-promoting portion derived from essential oils.

The present patent application is characterized essentially by a chemical formulation based on papain, urea, zinc sulfate and ubiquinol, the aim of which is to treat and heal skin affected by melasma, the formulation being composed of: 10% papain; 5% urea; 6% zinc sulfate and 5% ubiquinol, in a cream base q.s. 100g. This formulation must be produced by a trained professional who understands chemical processes and the use of each composition for proper handling. The product is for nighttime topical use, for any type of skin, and must be applied to clean, dry skin. The formulation should be applied to the area of the melasma and, once absorbed into the skin, sunscreen should be used on top of the product. The minimum period of treatment should be 6 to 12 months. Said formulation is considered to combat cellular senescence, repair the stratum corneum and the phospholipid bilayer of the cells, combat lipidic peroxidation and local inflammation, eliminate excess free radicals in the intracellular environment, reorganize the structure of internal organelles and preserve DNA, thereby maintaining homeostasis and skin health, healing and reducing dark spots, and leaving the skin healthier, soft, bright and moisturized.

The present invention proposes a gynecological antibacterial topical drug and its preparation method and application, which belong to the field of medical technology. Borneol acid is coupled with lysozyme, loaded on polydopamine, and embedded with polyethylene glycol to obtain a solid dispersion, and the Chinese medicine extract obtained by water extraction of Cnidium monnieri, Salvia miltiorrhiza, Rhubarb, Coptis chinensis, Magnolia officinalis, the antibacterial agent obtained by mixing nisin and natamycin, and menthol are mixed and added to a chitosan solution, and silver nitrate, poloxamer P407 and poloxamer P188 are added, and the mixture is stirred and mixed to obtain a gynecological antibacterial topical drug. The gynecological antibacterial topical drug prepared by the present invention has good antibacterial, antibacterial, anti-inflammatory and soothing effects, high bioavailability, delayed drug release, high drug stability, high patient compliance, and has broad application prospects.

To provide a topical skin composition that has moderate viscosity while exhibiting excellent stability over time. [Solution] A composition for topical use on the skin, comprising the following components (A) to (F): (A) a polyglycerin fatty acid ester in which R in the fatty acid-derived group R-COO- is an alkyl group having 13 to 23 carbon atoms or an alkenyl group having 13 to 23 carbon atoms; (B) a polyhydric alcohol of trivalent or higher; (C) a polyhydric alcohol of divalent value; (D) an oily component that is liquid at 25°C; (E) a compound represented by formula (I), its salts and mixtures thereof; and (F) a nonionic surfactant other than component (A) and component (E) with an HLB of 4.5 to 12.0, and substantially free of water.

The invention relates to a novel topical pharmaceutical composition comprising ceftizoxime, a third-generation cephalosporin antibiotic, complexed with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) to enhance solubility and stability in aqueous environments. The sterile, sprayable formulation is intended for direct topical use or dilution for the treatment and prevention of bacterial skin and wound infections. To overcome ceftizoxime's aqueous instability, the invention employs inclusion complexation with 2–10% w / v SBE-β-CD, prepared by shaking at 30°C for 72 hours followed by sterile filtration. Differential Scanning Calorimetry (DSC) confirms molecular encapsulation through suppression of the ceftizoxime melting peak, indicating loss of crystallinity. Antibacterial efficacy is demonstrated against Staphylococcus aureus and Escherichia coli using zone of inhibition assays. UV–Vis spectrophotometry at 258 nm confirms high linearity (R² = 0.998) for quantitative analysis. The formulation offers a stable, scalable, and patient-friendly alternative for localized antibiotic therapy and surgical prophylaxis with reduced systemic exposure.

The problem that this invention aims to solve is the development of a composition intended to protect the skin from ultraviolet rays and that does not have the drawbacks of the prior art. [Solution] The present invention relates to a topical composition that generates a photonic barrier from ultraviolet to visible light, comprising metal-doped crystalline bismuth oxide colloid Bi2O3.

The present invention relates to a gel or cream formulation for topical use, the formulation comprising beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts, where, based on 100 g of the gel or cream formulation, the content of the beta-D-mannuronic acid or alpha-L-guluronic acid or the mixture of beta-D-mannuronic acid and alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha-L-guluronic acid or alpha- the total amount of beta-D-mannuronic acid or alpha-L-guluronic acid or a mixture of beta-D-mannuronic acid and alpha-L-guluronic acid, their oligomers or their pharmaceutically acceptable salts is from 0.5 g to 40 g, said formulation further comprising caffeic acid. Furthermore, the present invention relates to a gel or cream formulation for topical use in a method of treating inflammation and / or any inflammatory response and / or pain, as well as a method of preparing the gel or cream formulation.

The present invention relates to a topical composition creating a photonic barrier from ultraviolet radiation to visible radiation, comprising bismuth oxide colloids Bi2O3 in crystalline form doped with a metal.

The invention relates to a cosmetic composition in the form of an oil-in-water emulsion free of petrolatum and paraffin. This composition comprises water, at least one polyol, 45 to 70% by weight of oily emollient(s), 4 to 15% by weight of waxy consistency factor(s), and at least one emulsifying agent chosen from sucrose and fatty acid esters. This composition proves to be particularly effective for the repair of damaged skin, when applied topically.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.